The global leukapheresis market is projected to reach USD 98 million by 2027 from USD 65 million in 2022, at a CAGR of 8.5%. The global leukopaks market is projected to reach USD 784 Million by 2027 from USD 146 Million in 2022, at a CAGR of 39.8%.
Emerging economies and increasing investments from academic institutes, pharma-biotech companies, and leading players are expected to provide growth opportunities for players in the market. On the other hand, high cost of therapeutic leukapheresis and leukopaks, and stringent donor recruitment criteria, are expected to restrain the market growth to a certain extent.
To know about the assumptions considered for the study download the pdf brochure
The Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US)
Terumo BCT, Inc.
Terumo BCT, Inc. (US) is a leading player in the blood component, therapeutic apheresis, and cellular technologies markets. Its extensive selection of products and technologies enable the company to withstand its competitive position in the global market. The company is strengthened by its innovative product portfolio in the leukapheresis market and extensive global sales network. For instance, in October 2018, the company collaborated with UniCAR Therapy Bio-Medicine Technology Co. (China) to provide its cell expansion devices to automate UniCARís cell therapy manufacturing process for chimeric antigen receptor (CAR) T-cell therapy.
Fresenius SE & Co. KGAA
Fresenius SE & Co. KGaA (US) is one of the leading companies in the leukapheresis market. Fresenius Kabi focuses on launching its products in emerging countries, and other inorganic growth strategies to gain a larger share of the market. In January 2020, Fresenius Kabi inaugurated an expansion of its transfusion and apheresis disposables plant in the Dominican Republic in Santa Domingo. Freseniusís continuous investments in R&D to optimize its portfolio and capital allocation strategies help fuel its future growth and ability to remain competitive in the healthcare business segment.
Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (US) held the first position in the global leukopaks market. The company conducts research, discovery, safety and efficacy, clinical support, and manufacturing. The company took to inorganic growth strategies (acquisitions) to strengthen its hold in the market. In January 2020, the company acquired HemaCare Corporation, a provider of human-derived cellular products, including leukopaks, which expanded Charles Riverís capabilities in the cell therapy market. In August 2020, the company acquired Cellero, a provider of cellular products for cell therapy developers and manufacturers.
Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE